RE: Skinbiotix11 Jan 2022 12:45
Confirms numbers we suspected, profitability point, and that he reads the forums.
Message sent.
Tue 11/01/2022 02:51
Good morning Stuart,
I wish you and our team well as our soft launch continues. One thing that has disturbed me is the broker forecast for sales in the next 6 months of 1.5M for the UK alone.
We know that USA sales will eclipse those sales by a good factor.
Are you really comfortable with those numbers or should it have been for all Axis sales.????
Think its really important to get somewhere near it as the 1.5M for UK axis alone does say to me to be widely ambitious. I'm currently in Lanzarote at the moment and if you say you stand by it, I'd be "over the moon", however would much rather go into this new year with realistic expectations.
Also want to avoid any huge loss of confidence which happened with me with another aim company (no names here), when similar huge broker growth rates didn't even come close.
Really appreciate your replies, it certainly makes a lot of difference to myself and a private small local consortium of investors.
Very best regards,
Alan Clark
and reply below.........
Good Morning Alan,
Thank you for your email and a Happy New Year to you.
As you know I am forbidden from commenting on forecasts and indeed am unable to provide them to the market. However, I agree that’s the number appears ambitious and I think many have misunderstood the meaning of a “soft launch”. We have spend literally nothing on marketing and as such, at this moment, can only reach those that are accessed via the various associations. What is important is that people understand that this product really does work and I am trying to build a global market here, to do that I need a strong foundation and not one built on quicksand. This will take time, but it will absolutely come. We are not a one trick pony and have multiple strands to deliver but we do so with a very limited headcount and a tiny marketing budget, which all in all makes this even more impressive in my most humble opinion. One thing is clear, we only need 2,200 subscriptions to get us to circa £1.2mill in revenue and circa 3,500 to get to break even. There are some potential wider strategic opportunities with Croda’s recent announcements which make us even more attractive to partner with, I will leave you to do your own research in that space.
Enjoy the sunshine in Lanzarote, it is rather crisp here to say the least.
Most sincerely,
Stuart
Stuart J. Ashman
Chief Executive Officer
SkinBioTherapeutics plc